Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Krishnan, A.; Cohen, A.; Trudel, S.; Spencer, A.; Lesokhin, A.; Wong, C.; Choeurng, V.; Cooper, J.; Sumiyoshi, T.; Goodman, G.; Jin, H. Y.; Sheikh, S.; Harrison, S. |
| Abstract Title: | Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM) |
| Meeting Title: | 19th International Myeloma Society Annual Meeting (IMS) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. |
| Meeting Dates: | 2022 Aug 25-27 |
| Meeting Location: | Los Angeles, CA |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-08-01 |
| Start Page: | S42 |
| End Page: | S43 |
| Language: | English |
| ACCESSION: | WOS:000895909200070 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(22)00342-1 |
| Notes: | Meeting Abstract: P-012 -- Source: Wos |
